Dementia is the 5th leading cause of death in the US and one of the biggest public health crises we are facing today. As we become more advanced at treating other leading causes of death, the proportion of Americans living longer, and thus living with dementia, will increase. It is important to identify at risk individuals earlier before potentially irreversible changes in the brain occur. Biomarkers for early cognitive decline will allow tracking and intervention through healthy lifestyle and the novel therapeutics that we and others are creating. Here, we are piloting a novel risk/susceptibility predictor for Alzheimer’s Disease based on multi-omics biological aging biomarkers in blood.